Alzheimer’s disease: newer modalities in treatment
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20243045Keywords:
AD, Monoclonal antibody, Degenerative brain disease, Clinical development for ADAbstract
Alzheimer’s disease (AD) remains insurmountable despite a long history of research and clinical development. It is projected to rise in the coming decades of public health due to the aging population worldwide. Understanding the basic tenets of the disease and targeting key steps remains a time-tested approach even for AD. Apart from the currently available treatment options namely NMDA blockers, and acetylcholinesterase inhibitors, recently monoclonal antibodies that target Aβ amyloid protein are approved. This review highlights the key features of currently approved drugs along with promising drugs in clinical development.
Metrics
References
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-7.
Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12:1-27.
Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020;12:1179573520907397.
Dautzenberg G, Lijmer J, Beekman A. Diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for cognitive screening in old age psychiatry: Determining cutoff scores in clinical practice. Avoiding spectrum bias caused by healthy controls. Int J Geriatr Psychiatr. 2020;35(3):261-9.
Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res. 2018;7:F1000Faculty Rev-1161.
Zou K, Abdullah M, Michikawa M. Current Biomarkers for Alzheimer's Disease: From CSF to Blood. J Pers Med. 2020;10(3):85.
Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020;12:1179573520907397.
Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf. 1998;19(6):465-80.
Blackard WG Jr, Sood GK, Crowe DR, Fallon MB. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol. 1998;26(1):57-9.
Giacobini E. Selective inhibitors of butyrylcholinesterase: A valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8.
Schegg KM, Harrington LS, Neilsen S. Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease. Neurobiol Aging. 1992;13(6):697-704.
Mesulam M, Guillozet A, Shaw P, Quinn B. Widely spread butyryl cholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9(1):88-93.
Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4(4):273-7.
Froelich L, Gertz H-J, Heun R, Heuser I, Jendroska K, Kornhuber J, et al. Donepezil for Alzheimer’s disease in clinical practice-the DONALD study. Dement Geriatr Cogn Disord. 2004;18(1):37-43.
Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer’s disease. Int Psychogeriatr. 2000;12(3):389-401.
Gauthier S, Feldman H, Hecker J, Bruno V, David A, Ponni S, et al. Donepezil MSAD Study Investigators Group Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002;14(4):389-404.
Albuquerque EX, Alkondon M, Pereira EFR, Castro NG, Schrattenholz A, Barbosa CTF, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997;280(3):1117-36.
Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther. 2005;315(3):1346-53.
Mayoclinic.org. 2024. Galantamine (Oral Route) Side Effects-Mayo Clinic. Available at: https://www.mayoclinic.org/drugs-supplements/galantamine-oral-route/side-effects/drg-20067458?p=1#:~:text=Galantamine%20may%20cause%20stomach%20or,get%20emergency%20help%20at%20once. Accessed on 12 August 2024.
Burn S. Galantamine Oral: Uses, Side Effects, Interactions, Pictures, Warnings and Dosing. WebMD. 2024. Available at: https://www.webmd.com/drugs/2/drug-20737-6218/galantamine-oral/galantamine-oral/details. Accessed on 12 August 2024.
Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249-58.
Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging. 2017;12:697-707.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-25.
Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;(127):45-63.
Chneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: An appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251-83.
Allgaier M, Allgaier C. An update on drug treatment options of Alzheimer’s disease. Front Biosci (Landmark Ed.). 2014;19(8):1345-54.
Beurel E, Jope RS. Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience. 2010;169(3):1063-70.
Wang X, She H, Mao Z. Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem. 2009;284(47):32619-26.
Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78(6):1219-32.
Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell. 2005;120(1):137-49.
Walsh DM, Selkoe DJ. Amyloid β-protein and beyond: The path forward in Alzheimer’s disease. Curr Opin Neurobiol. 2020;61:116-24.
Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimer's Dementia. 2012;8(2):131-68.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-6.
Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545-55.
Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Translat Med. 2011;3(77):77sr1.
Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, Wojtowicz JM, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci. 1997;17(13):5196-205.
Van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2019;76(10):1219-29.
Arndt JW, Qian F, Smith BA, Quan C, Kilambi KP, Bush MW, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep. 2018;8(1):6412.
Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update. J Biomed Sci. 2023;30(1):83.
Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease. JAMA Neurol. 2022;79(1):13-21.
Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.
Sims JR, Zimmer JA, Evans CD, Ming L, Paul A, JonDavid S, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-27.
Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease. J Neurosci Res. 1999;57(3):295-303.
Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 2001;58:487-92.
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000;20:5709-14.
McGeer PL, McGeer EG. Mechanisms of cell death in Alzheimer's disease-immunopathology. J Neuronal Transmission. 1998;54:159-66.
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurol. 1997;48(3):626-32.
Ali N, Sohail R, Jaffer SR, Siddique S, Kaya B, Atowoju I, et al. The Role of Estrogen Therapy as a Protective Factor for Alzheimer's Disease and Dementia in Postmenopausal Women: A Comprehensive Review of the Literature. Cureus. 2023;15(8):e43053.
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer’s Disease. N Eng J Med. 1997;336(17):1216-22.
Lauretti E, Ozlem D, Domenico P. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochem Biophys Molecular Cell Res. 2020;1867(5):118664.
Downloads
Published
How to Cite
Issue
Section
